Literature DB >> 7505976

Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin.

H Lilja1.   

Abstract

Prostate specific antigen is an abundant prostate-derived serine protease in the seminal fluid. Low concentrations of the protein are normally released into blood, but above normal concentrations are frequently detected in prostate disease. The PSA-ACT complex is the predominant molecular form of serum PSA (up to approximately 95%) although complex formation is slow between the purified proteins in vitro. A free, noncomplexed form of PSA constitutes a minor fraction of the serum PSA, although serum ACT occurs in large molar excess. The free, noncomplexed form of serum PSA is reported to constitute a significantly smaller proportion of the PSA in untreated prostate cancer than in BPH. The molecular basis for this finding is unclear, but measurements of the proportion of the free form of serum PSA or the proportion of serum PSA-ACT may facilitate discrimination between prostate cancer and BPH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505976

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  8 in total

1.  [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.

Authors:  Brian V Le; Christopher R Griffin; Stacy Loeb; Gustavo F Carvalhal; Donghui Kan; Nikola A Baumann; William J Catalona
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

2.  Equivalent recognition of free and ACT-complexed PSA in a monoclonal-polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody.

Authors:  Z Zhou; E G Armstrong; A Belenky; J V Freeman; K K Yeung
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

Review 3.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

Review 4.  The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer.

Authors:  P T Scardino
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

Review 5.  Management of elevated prostate-specific antigen in men with nonbacterial chronic prostatitis.

Authors:  Jaspreet S Sandhu
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

6.  Assays for prostate cancer : changing the screening paradigm?

Authors:  Jens Hansen; Michael Rink; Markus Graefen; Shahrokh Shariat; Felix K-H Chun
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

Review 7.  Screening for prostate cancer.

Authors:  M L Cher; P R Carroll
Journal:  West J Med       Date:  1995-03

Review 8.  Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer.

Authors:  Prosper Kanyong; Sean Rawlinson; James Davis
Journal:  J Cancer       Date:  2016-02-10       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.